Merestinib Completed Phase 1 Trials for Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01285037A Study of LY2801653 in Advanced Cancer